Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Yale
•
Triple negative
•
NCI-CCC Breast Tumor Board Question
How would you manage patients with TNBC who achieve a pCR with neoadjuvant KEYNOTE-522 regimen, but develop isolated chest wall recurrence soon after completing neoadjuvant treatment?
Would you provide adjuvant therapy? Palliative therapy?
No evidence of distance metastases.
Related Questions
What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
In which situations are you comfortable with alternative dosing of ovarian suppression (e.g Lupron q3m) for premenopausal patients during adjuvant breast cancer treatment?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?